Rani Therapeutics Holdings (RANI) Cash from Operations (2020 - 2026)

Rani Therapeutics Holdings has reported Cash from Operations for 7 years, with the latest figure at -$9.0 million in Q2 2026.

• On a quarterly basis, Cash from Operations fell 55.68% year-over-year to -$9.0 million in Q2 2026; TTM through Jun 2026 was -$20.3 million, a 34.56% increase from a year earlier, with the FY2025 full-year figure at -$18.7 million, up 47.28% from the prior year.
• Cash from Operations was -$9.0 million for Q2 2026 at Rani Therapeutics Holdings, down from -$6.5 million in the prior quarter.
• The five-year high for Cash from Operations was $294000.0 in Q4 2025, with the low at -$14.6 million in Q4 2022.
• Average Cash from Operations over 5 years is -$9.3 million, with a median of -$9.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations plunged 131.23% in 2022, then surged 103.4% in 2025.
• Over 5 years, Cash from Operations stood at -$14.6 million in 2022, then climbed by 14.7% to -$12.5 million in 2023, then surged by 30.64% to -$8.7 million in 2024, then soared by 103.4% to $294000.0 in 2025, then tumbled by 3169.05% to -$9.0 million in 2026.
• The last three Cash from Operations figures came in at -$9.0 million (Q2 2026), -$6.5 million (Q1 2026), and $294000.0 (Q4 2025), per Business Quant data.